Company: HCTI
Filing Date: 2025-05-09
Form Type: S-1/A
Source: 0001213900-25-041190
Chunk: 15

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-09
Form: S-1/A
Chunk 15
---
 the Panel’s approval
our appeal to regain compliance with the Stockholders’ Equity Rule (as defined under “The Private Placement”) as described
in more detail under “The Private Placement,” the Panel informed us that we are not eligible for an extension of the Compliance
Period and if we do not regain compliance with the Bid Price Rule during the Compliance Period, our Common Stock will be delisted. There
can be no assurance that we will regain such compliance during the Compliance Period.

Any delisting determination by Nasdaq could
seriously decrease or eliminate the value of an investment in our Common Stock and other securities linked to our Common Stock. While
a listing on an over-the-counter exchange could maintain some degree of a market in our Common Stock, we could face substantial material
adverse consequences, including, but not limited to, the following: limited availability for market quotations for our Common Stock;
reduced liquidity with respect to and decreased trading prices of our Common Stock; a determination that shares of our Common Stock are
“penny stock” under the Securities and Exchange Commission rules, subjecting brokers trading our Common Stock to more stringent
rules on disclosure and the class of investors to which the broker may sell the Common Stock; limited news and analyst coverage for our
Company, in part due to the “penny stock” rules; decreased ability to issue additional securities or obtain additional financing
in the future; and potential breaches under or terminations of our agreements with current or prospective large stockholders, strategic
investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect the market
price of our securities and trading volume of our Common Stock.

Furthermore, on May 7, 2025, the closing price
of our Common Stock was $0.1909. Pursuant to Nasdaq Rule 5810(c)(3)(A)(iii), if the closing price of our Common Stock is $0.10 or less
for 10 consecutive trading days, we will be issued a Nasdaq delisting determination notice. The likelihood of our Common Stock trading
below $0.10 for 10 consecutive trading days is significantly increased by registration of Purchase Warrants under the registration statement
related to this prospectus as up to 361,904,850 shares of our Common Stock could be issued at an exercise price as low as $0.084 per
share pursuant to the Series A Warrants and up to 1,085,714,550 shares of our Common Stock